Prion-Like Seeding of Misfolded α-Synuclein in the Brains of Dementia with Lewy Body Patients in RT-QUIC

Molecular Neurobiology

Volumn 55, Issue 5, 2018, Pages 3916-3930

  Sano, Kazunori ^a   Atarashi, Ryuichiro ^b   Satoh, Katsuya ^c   Ishibashi, Daisuke ^c   Nakagaki, Takehiro ^c   Iwasaki, Yasushi ^d   Yoshida, Mari ^d   Murayama, Shigeo ^e   Mishima, Kenichi ^a   Nishida, Noriyuki ^c  

^a FUKUOKA UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^d AICHI MEDICAL UNIVERSITY   (Japan)

^e Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology   (Japan)

Author keywords

Dementia with Lewy bodies (DLB); Prion; Real time quaking induced conversion (RT QUIC); synuclein

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMER; RECOMBINANT ALPHA SYNUCLEIN; SERINE; UNCLASSIFIED DRUG; PHOSPHOSERINE; PROTEIN AGGREGATE; RECOMBINANT PROTEIN;

AMINO ACID METABOLISM; ARTICLE; ASSAY; BRAIN TISSUE; CIRCULAR DICHROISM; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DNA SEQUENCE; ESCHERICHIA COLI; FIBRIL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFRARED SPECTROSCOPY; NERVOUS SYSTEM PARAMETERS; OLIGOMERIZATION; PATHOGENESIS; PHOSPHORYLATION; PRION; PROTEIN EXPRESSION; PROTEIN MISFOLDING; PROTEIN PURIFICATION; QUANTITATIVE ANALYSIS; REAL TIME QUAKING INDUCED CONVERSION ASSAY; SEEDING DOSE; SEQUENCE ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; BIOASSAY; BRAIN; CHEMISTRY; DEMENTIA; METABOLISM; PATHOLOGY; PROCEDURES; PROTEIN FOLDING; SOLUBILITY;

ALPHA-SYNUCLEIN; BIOLOGICAL ASSAY; BRAIN; DEMENTIA; HUMANS; LEWY BODY DISEASE; PHOSPHORYLATION; PHOSPHOSERINE; PRIONS; PROTEIN AGGREGATES; PROTEIN FOLDING; RECOMBINANT PROTEINS; SOLUBILITY;

EID: 85019740998     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-017-0624-1     Document Type: Article

References (43)

1. Fujiwara H, Hasegawa M, Dohmae N et al (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164
2. Smith WW, Margolis RL, Li X et al (2005) Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci: the official journal of the Society for Neuroscience 25:5544–5552
3. Paleologou KE, Schmid AW, Rospigliosi CC et al (2008) Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 283:16895–16905
4. Chen L, Feany MB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8:657–663
5. Gorbatyuk OS, Li S, Sullivan LF et al (2008) The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 105:763–768
6. Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C et al (2009) Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson’s disease. Hum Mol Genet 18:872–887
7. McFarland NR, Fan Z, Xu K et al (2009) Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol 68:515–524
8. Braak H, Del Tredici K, Rub U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
9. Braak H, Rub U, Jansen Steur EN et al (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410
10. Kordower JH, Chu Y, Hauser RA et al (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 14:504–506
11. Li JY, Englund E, Holton JL et al (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 14:501–503
12. Luk KC, Kehm VM, Zhang B et al (2012) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 209:975–986
13. Mougenot AL, Nicot S, Bencsik A et al (2012) Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 33:2225–2228
14. Watts JC, Giles K, Oehler A et al (2013) Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A 110:19555–19560
15. Masuda-Suzukake M, Nonaka T, Hosokawa M et al (2013) Prion-like spreading of pathological alpha-synuclein in brain. Brain: a journal of neurology 136:1128–1138
16. Volpicelli-Daley LA, Luk KC, Patel TP et al (2011) Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72:57–71
17. Luk KC, Kehm V, Carroll J et al (2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (New York, NY) 338:949–953
18. Atarashi R, Satoh K, Sano K et al (2011) Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 17:175–178
19. Sano K, Atarashi R, Ishibashi D et al (2014) Conformational properties of prion strains can be transmitted to recombinant prion protein fibrils in real-time quaking-induced conversion. J Virol 88:11791–11801
20. Fairfoul G, McGuire LI, Pal S et al (2016) Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 3:812–818
21. Wang W, Perovic I, Chittuluru J et al (2011) A soluble alpha-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A 108:17797–17802
22. Bartels T, Choi JG, Selkoe DJ (2011) Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477:107–110
23. Wilham JM, Orru CD, Bessen RA et al (2010) Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog 6:e1001217
24. Thannickal TC, Lai YY, Siegel JM (2007) Hypocretin (orexin) cell loss in Parkinson’s disease. Brain: a journal of neurology 130:1586–1595
25. Paleologou KE, Oueslati A, Shakked G et al (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci: the official journal of the Society for Neuroscience 30:3184–3198
26. Vlad C, Lindner K, Karreman C et al (2011) Autoproteolytic fragments are intermediates in the oligomerization/aggregation of the Parkinson’s disease protein alpha-synuclein as revealed by ion mobility mass spectrometry. Chembiochem: a European journal of chemical biology 12:2740–2744
27. Chatani E, Lee YH, Yagi H et al (2009) Ultrasonication-dependent production and breakdown lead to minimum-sized amyloid fibrils. Proc Natl Acad Sci U S A 106:11119–11124
28. Xue WF, Hellewell AL, Gosal WS et al (2009) Fibril fragmentation enhances amyloid cytotoxicity. J Biol Chem 284:34272–34282
29. Danzer KM, Krebs SK, Wolff M et al (2009) Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem 111:192–203
30. Danzer KM, Haasen D, Karow AR et al (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci: the official journal of the Society for Neuroscience 27:9220–9232
31. Brown DR (2010) Oligomeric alpha-synuclein and its role in neuronal death. IUBMB life 62:334–339
32. Vekrellis K, Xilouri M, Emmanouilidou E et al (2011) Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 10:1015–1025
33. Paleologou KE, Kragh CL, Mann DM et al (2009) Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain: a journal of neurology 132:1093–1101
34. Salvadores N, Shahnawaz M, Scarpini E et al (2014) Detection of misfolded Abeta oligomers for sensitive biochemical diagnosis of Alzheimer’s disease. Cell Rep 7:261–268
35. Tanaka M, Kim YM, Lee G et al (2004) Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 279:4625–4631
36. Lue LF, Walker DG, Adler CH et al (2012) Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol (Zurich, Switzerland) 22:745–756
37. Perfeito R, Lazaro DF, Outeiro TF et al (2014) Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells. Mol Cell Neurosci 62:51–59
38. Chau KY, Ching HL, Schapira AH et al (2009) Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson’s disease pathogenesis. J Neurochem 110:1005–1013
39. Kuwahara T, Tonegawa R, Ito G et al (2012) Phosphorylation of alpha-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. J Biol Chem 287:7098–7109
40. Morales R, Moreno-Gonzalez I, Soto C (2013) Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog 9:e1003537
41. Kasuga K, Nishizawa M, Ikeuchi T (2012) Alpha-synuclein as CSF and blood biomarker of dementia with Lewy bodies. Int J Alzheimers Dis 2012:437025
42. Tokuda T, Qureshi MM, Ardah MT et al (2010) Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75:1766–1772
43. Hansson O, Hall S, Ohrfelt A et al (2014) Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther 6:25